Tourmaline Bio, Inc.

Tourmaline Bio, Inc.

TRML·NASDAQ

$47.98

+0.0000%
HealthcareBiotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

At a Glance

Live Snapshot
Market Cap$1.23B
EPS-2.8900
P/E Ratio-7.02
Earnings Date04/30/2026

trml

Total Equity

Last Annual Value

300.05M

3-Year CAGR

7%

5-Year CAGR

50%

10-Year CAGR

22%

Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Competitors Analysis of Total Equity

TRML · NASDAQ
CompanyTotal Equity
CAGR 3Y
CAGR 5Y
CAGR 10Y
300.05M
13.5%4.3%N/A 
305.26M
-11.0%N/AN/A
493.40M
43.0%23.4%49.2%
459.60M
23.2%33.9%N/A
384.36M
19.7%7.1%N/A
PGEN logo
Precigen, Inc.
NASDAQ:PGEN
20.91M
-43.9%-27.9%-28.1%
567.06M
-9.0%-8.8%N/A
64.63M
-51.1%-30.8%-2.6%
1.01B
58.0%44.4%N/A
Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Fair Value Envelope

TRML · NASDAQ

Our analysis suggests that TRML has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $47.98, this represents a potential HIDDEN relative to our calculated worth for Tourmaline Bio, Inc..

Intrinsic Value
Current Price: $47.98